@article{10.37349/etat.2023.00198,
abstract = {Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of therapy remains an unanswered question for a subset of mTNBC patients who harbor germline breast cancer gene 1/2 (BRCA1/2; gBRCA1/2) mutation. This article aims to offer insights into the optimal therapy sequencing for mTNBC patients with gBRCA1/2 mutations and its impact on clinical decision-making. The perspective offered is based on the best currently available data and propose a practical algorithm to guide the management of this subgroup in the frontline setting.},
author = {Alaklabi, Sabah and Roy, Arya Mariam and Chaudhary, Lubna N. and Gandhi, Shipra},
doi = {10.37349/etat.2023.00198},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {1301--1309},
title = {{Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002198},
volume = {4},
year = {2023},
number = {6}
}